![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue and T Tanaka
Department of Internal Medicine (I), Daisan Hospital, Jikei University School of Medicine, Tokyo, Japan.
Solute-free water diuretics (aquaretics) that antagonize hydrosmotic vasopressin 2 (V2) receptors may be useful in treating diseases in which water is retained. An orally active, nonpeptide, selective V2 antagonist (OPC-31260) was administered in six dose steps (3, 15, 30, 60, 100 and 200 mg) to six healthy, normally hydrated men to investigate the aquaretic effects in comparison with 12 placebo-treated control subjects (two at each dose). All subjects tolerated all six doses without serious clinical side effects. OPC-31260 increased the first 6-hr hypotonic urine volume dose-dependently. Administration at 30 mg raised the 6-hr urine volume to 2 times, 100 mg to 3 times and 200 mg to 4 times (1828.0 +/- 130.2 ml/6 hr) that of the placebo group (470.4 +/- 52.1 ml/6 hr). The drug increased urine flow maximally between 1 and 1.5 hr at all doses (e.g., 10.0 +/- 0.7-10.8 +/- 0.4 ml/min at 60-200 mg). The drug rapidly lowered urine osmolality for 4 hr, particularly between 60 and 90 min (e.g., 72.3 +/- 2.3 and 62.3 +/- 5.1 mOsm/kg at 100 and 200 mg, respectively). In marked hypotonic diuresis, mean free-water clearance of the 6-hr urine increased dose- proportionally into the positive range, reaching 2.82 +/- 0.21 ml/min at 200 mg.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  B. Yangthara, A. Mills, V. Chatsudthipong, L. Tradtrantip, and A. S. Verkman Small-Molecule Vasopressin-2 Receptor Antagonist Identified by a G-Protein Coupled Receptor "Pathway" Screen Mol. Pharmacol., July 1, 2007; 72(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Robben, M. Sze, N. V. A. M. Knoers, and P. M. T. Deen Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus Am J Physiol Renal Physiol, January 1, 2007; 292(1): F253 - F260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Bennett V2 Receptor Antagonists in Cystic Kidney Diseases: An Exciting Step towards a Practical Treatment J. Am. Soc. Nephrol., April 1, 2005; 16(4): 838 - 839. [Full Text] [PDF]
|
|
|
|
|
|
N. Hadrup, J. S. Petersen, J. Praetorius, E. Meier, M. Graebe, L. Brond, D. Staahltoft, S. Nielsen, S. Christensen, D. R. Kapusta, et al. Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation Am J Physiol Renal Physiol, July 1, 2004; 287(1): F160 - F168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bardoux, P. Bruneval, D. Heudes, N. Bouby, and L. Bankir Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1755 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bankir Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects Cardiovasc Res, August 15, 2001; 51(3): 372 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Wong and J. G. Verbalis Vasopressin V2 receptor antagonists Cardiovasc Res, August 15, 2001; 51(3): 391 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Palm, D. Reimann, and P. Gross The role of V2 vasopressin antagonists in hyponatremia Cardiovasc Res, August 15, 2001; 51(3): 403 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Birnbaumer The V2 vasopressin receptor mutations and fluid homeostasis Cardiovasc Res, August 15, 2001; 51(3): 409 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pouzet, C. Serradeil-Le Gal, N. Bouby, J.-P. Maffrand, G. Le Fur, and L. Bankir Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus Nephrol. Dial. Transplant., April 1, 2001; 16(4): 725 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bardoux, H. Martin, M. Ahloulay, F. Schmitt, N. Bouby, M.-M. Trinh-Trang-Tan, and L. Bankir Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: Study in vasopressin-deficient Brattleboro rats PNAS, August 31, 1999; 96(18): 10397 - 10402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Burrell, P. A. Phillips, J. Risvanis, R. K. Chan, K. L. Aldred, and C. I. Johnston Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H176 - H182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Saito, S.-e Ishikawa, K. Abe, K. Kamoi, K. Yamada, K. Shimizu, T. Saruta, and S. Yoshida Acute Aquaresis by the Nonpeptide Arginine Vasopressin (AVP) Antagonist OPC-31260 Improves Hyponatremia in Patients with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1054 - 1057. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
